Sign up to save your podcasts
Or
Share Anthony R. Mato - The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell Cancers
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Anthony R. Mato - The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell Cancers
Go online to PeerView.com/CZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Covalent BTK inhibitors have transformed the care of B-cell cancers such as CLL/SLL and MCL, but challenges to optimal care remain. How well do you understand the barriers to consistent, efficacious treatment with BTK-based treatment and what that means for treatment planning across multiple lines of therapy? During this activity, experts will tackle these questions and demonstrate how to strategically plan for and implement management protocols that address clinical problems such as BTK inhibitor resistance and intolerance. Throughout, the panelists will share insights on evidence-based and effective sequential therapy (including with second-generation covalent BTK inhibitors, noncovalent BTK options, and non–BTK inhibitor agent classes) and use case-based discussion to illustrate how therapeutic challenges associated with BTK inhibitor therapy can be overcome. Upon completion of this CE activity, participants will be able to: Develop plans to capture therapeutic intolerance or BTK resistance mutations before or at disease progression in patients receiving treatment with covalent BTK inhibitors, Select evidence-based sequential therapy for patients with CLL/SLL or MCL who are progressing on a covalent BTK inhibitor with resistance mutations, Recommend appropriate sequential options for patients with B-cell cancers who exhibit therapeutic intolerance to BTK inhibitors in order to maximize safety, ensure continued efficacy, and augment patient quality of life.
View all episodes
By PVI, PeerView Institute for Medical Education
4.1
2525 ratings
Go online to PeerView.com/CZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Covalent BTK inhibitors have transformed the care of B-cell cancers such as CLL/SLL and MCL, but challenges to optimal care remain. How well do you understand the barriers to consistent, efficacious treatment with BTK-based treatment and what that means for treatment planning across multiple lines of therapy? During this activity, experts will tackle these questions and demonstrate how to strategically plan for and implement management protocols that address clinical problems such as BTK inhibitor resistance and intolerance. Throughout, the panelists will share insights on evidence-based and effective sequential therapy (including with second-generation covalent BTK inhibitors, noncovalent BTK options, and non–BTK inhibitor agent classes) and use case-based discussion to illustrate how therapeutic challenges associated with BTK inhibitor therapy can be overcome. Upon completion of this CE activity, participants will be able to: Develop plans to capture therapeutic intolerance or BTK resistance mutations before or at disease progression in patients receiving treatment with covalent BTK inhibitors, Select evidence-based sequential therapy for patients with CLL/SLL or MCL who are progressing on a covalent BTK inhibitor with resistance mutations, Recommend appropriate sequential options for patients with B-cell cancers who exhibit therapeutic intolerance to BTK inhibitors in order to maximize safety, ensure continued efficacy, and augment patient quality of life.
More shows like PeerView Internal Medicine CME/CNE/CPE Audio Podcast
View all
JAMA Editors' Summary
131 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
11 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
27 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
10 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
3 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
4 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
NEJM This Week
325 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
10 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners
JAMA Clinical Reviews
493 Listeners
Mayo Clinic Talks
280 Listeners
Frankly Speaking About Family Medicine
253 Listeners
The Curbsiders Internal Medicine Podcast
3,332 Listeners
The Daily
111,864 Listeners
Up First from NPR
56,221 Listeners
JAMA Medical News
90 Listeners
Core IM | Internal Medicine Podcast
1,095 Listeners
This Podcast Will Kill You
16,855 Listeners
The Clinical Problem Solvers
519 Listeners
Throughline
16,043 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
349 Listeners
Cardionerds: A Cardiology Podcast
427 Listeners